drugset / Trial / NCT03241784
Ph1 T-Regulatory Cells in Amyotrophic Lateral Sclerosis
Phase 1
Completed
3 enrolled
The Methodist Hospital Research Institute
M.D. Anderson Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
Open-label pilot study to determine the safety and tolerability of autologous CD4+ CD25+ regulatory T cells infusions with concomitant subcutaneous IL-2 injections taken 3 times per week in 3 participants with ALS.
Timeline
- Start
- 2016-05-16
- Primary completion
- 2018-01-05
- Completion
- 2018-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous T-regulatory lymphocytes | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 200000 unknown | Subcutaneous |